Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis.

Geburtshilfe Frauenheilkd · 2018 · PMC6109715 · PMID 30158716

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

a statistical trendp = 0.072so close (0.05 < p ≤ 0.1)

A statistical trend in favour of the combined therapy with bevacizumab could be identified (42.9% [n = 6/14] vs. 12.5% n = 2/16]; p = 0.072).

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.